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Abstract
Ubiquitylation of outer mitochondrial membrane (OMM) proteins is
closely related to the onset of familial Parkinson’s disease. Typi-
cally, a reduction in the mitochondrial membrane potential results
in Parkin-mediated ubiquitylation of OMM proteins, which are then
targeted for proteasomal and mitophagic degradation. The role of
ubiquitylation of OMM proteins with non-degradative fates,
however, remains poorly understood. In this study, we find that the
mitochondrial E3 ubiquitin ligase MITOL/March5 translocates from
depolarized mitochondria to peroxisomes following mitophagy
stimulation. This unusual redistribution is mediated by peroxins
(peroxisomal biogenesis factors) Pex3/16 and requires the E3 ligase
activity of Parkin, which ubiquitylates K268 in the MITOL C-
terminus, essential for p97/VCP-dependent mitochondrial extrac-
tion of MITOL. These findings imply that ubiquitylation directs
peroxisomal translocation of MITOL upon mitophagy stimulation
and reveal a novel role for ubiquitin as a sorting signal that allows
certain specialized proteins to escape from damaged mitochondria.
Keywords March5; peroxin; PINK1- and Parkin-mediated mitophagy;
ubiquitin; VCP
Subject Categories Autophagy & Cell Death; Post-translational Modifications &
Proteolysis
DOI 10.15252/embr.201947728 | Received 15 January 2019 | Revised 30 August
2019 | Accepted 11 September 2019 | Published online 10 October 2019
EMBO Reports (2019) 20: e47728
Introduction
The mitochondria are a well-organized organelle. When the mito-
chondrial membrane potential is decreased, PINK1 and Parkin,
which are causal gene products of inherited Parkinson’s disease,
play pivotal roles in the selective degradation of damaged
mitochondria via the proteasome and autophagy pathway (the
following is called mitophagy). PINK1 is a Ser/Thr kinase, and
Parkin is an RBR-type E3 (ubiquitin ligase) that catalyzes ubiquitin
conjugation to protein substrates from a ubiquitin-adducted E2
(ubiquitin-conjugating enzyme) [1–9]. PINK1 accumulates on
damaged mitochondria and subsequently phosphorylates Ser65 of
both ubiquitin and ubiquitin-like (Ubl) domain of Parkin [10–15].
Through the interaction with phosphorylated ubiquitin, Parkin also
becomes phosphorylated, which triggers auto-activation and subse-
quent conformational changes [16–18]. Ubiquitylation of various
mitochondrial proteins by the activated Parkin then leads to selec-
tive elimination of damaged mitochondria [19–31].
MITOL/March5 is a RING-type E3 with four transmembrane
domains that is integrated into the outer mitochondrial membrane
[32–34]. It has been reported that MITOL regulates mitochondrial
morphology via association with and ubiquitylation of the mito-
chondrial fission factors, Fis1 and Drp1 [34]. Indeed, siRNA-
mediated knockdown of MITOL resulted in mitochondrial fragmen-
tation. MITOL is also known to ubiquitylate mitochondrial mitofus-
in2 (MFN2), which leads to the tethering of mitochondria to the
endoplasmic reticulum (ER) [33,35,36].
When we investigated whether a mitochondrial E3(s) cooperate
with Parkin to eliminate damaged mitochondria [37], we noticed
that MITOL showed ectopic localization during Parkin-mediated
mitochondrial ubiquitylation. This finding is of interest as the
disconnected localization of MITOL and mitochondria had not been
previously reported. In this study, we found that both overexpressed
and endogenous MITOL translocated from damaged mitochondria to
peroxisomes in response to mitochondrial depolarization. Notably,
MITOL translocation was completely dependent on PINK1 and the
E3 activity of Parkin with ubiquitylation of MITOL at K268 triggering
mitochondrial extraction in a p97/VCP-dependent manner. Further-
more, peroxin-dependent translocation of MITOL was also observed,
suggesting that the p97/VCP–peroxin axis regulates ubiquitylated
MITOL translocation following mitophagy stimulation.
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Results
MITOL redistributes to peroxisomes in response to mitochondrial
depolarization in a Parkin-dependent manner
To understand the molecular details of MITOL localization when the
mitochondrial membrane potential is decreased, C-terminal HA-tagged
MITOL and Flag-Parkin were transiently expressed in HeLa cells.
Cells treated with or without the uncoupler CCCP (carbonyl cyanide
m-chlorophenylhydrazone) were stained with anti-HA and anti-
Tom20/TOMM20 antibodies (Fig 1A). Without CCCP treatment,
MITOL-HA overlapped with the mitochondrial outer membrane
protein Tom20, indicating its mitochondrial localization. Interest-
ingly, after 3 h of CCCP treatment, a large population of MITOL
clustered in dot-like structures that did not co-localize with Tom20,
and we assumed that MITOL had localized in another organelle
rather than the cytosol. To clarify MITOL localization after mito-
phagy stimulation, we first performed co-immunostaining experi-
ments using various organelle markers. The MITOL-HA-positive
dot-like structures were not coincident with the immunostaining
patterns of Sec61b (ER marker) or LAMP1 (lysosome marker; Fig 1B
and C), but did largely co-localize with catalase (peroxisome marker)
after 3 h of CCCP treatment (Fig 1D and F). Next, co-localization
between MITOL and each marker protein was assessed as a Pearson
correlation coefficient. The quantitative analysis supported our
aforementioned findings that co-localization between MITOL and
Tom20 was significantly decreased following CCCP treatment for
3 h (Fig 1E, columns 1 and 2). Although a small percentage of
MITOL was merged with catalase in the absence of CCCP treatment,
the co-localization markedly increased in response to CCCP treat-
ment for 3 h (Fig 1E, columns 7 and 8). Peroxisomal membrane
protein PMP34 fused with FusionRed at its C-terminus (PMP34-
FusionRed) also co-localized with MITOL-GFP in Parkin-expressing
HeLa cells after 3 h of CCCP treatment (Fig 1G), and this co-localization
was confirmed by quantitative analysis (Fig 1H). In addition, the
peroxisomal localization of MITOL following dissipation of the mito-
chondrial membrane potential was unaffected by C-terminal addi-
tion of the 3Flag epitope (Appendix Fig S1A). Cells exposed to the
potassium ionophore valinomycin (another type of mitochondrial
uncoupler) for 3 h also exhibited MITOL and catalase co-localization,
suggesting that peroxisomal localization of MITOL was not an arti-
fact of CCCP treatment (Appendix Fig S1B). These results indicate
that MITOL moves to peroxisomes in response to mitophagy stimu-
lation. Next, we tested the possibility that peroxisomes are the
halfway point of a translocation process that leads to another orga-
nelle. Following extended CCCP treatment, HeLa cells stably
expressing HA-Parkin and 3Flag-MITOL were stained with Pex14
(Appendix Fig S2A), Sec61b (Appendix Fig S2B), and Tom20
(Appendix Fig S2C: because Tom20 was substantially degraded via
mitophagy for > 12 h, Tom20-positive cells were selected to be
shown). MITOL and Pex14 co-localization peaked within 3 h of
CCCP treatment and then dispersed over time. However, even with
extended CCCP treatment, we found no evidence of MITOL co-loca-
lization with Tom20 or Sec61b.
PINK1 and the E3 activity of Parkin are required for MITOL
redistribution to peroxisomes
Next, we investigated whether Parkin is required for the redistribu-
tion of MITOL from impaired mitochondria to peroxisomes. For this
purpose, MITOL-HA was transfected into HeLa cells that lack a func-
tional PARK2 gene by genomic mutation [4,38]. As expected,
MITOL-HA moved to peroxisomes in HeLa cells stably expressing
GFP-Parkin after 3 h of CCCP treatment and did not merge with
Tom20 (Fig 2A, bottom panel). In contrast, MITOL-HA was retained
on mitochondria after CCCP treatment in HeLa cells lacking endo-
genous Parkin expression (Fig 2A, upper panel). Valinomycin-
treated cells showed the same phenomena (Appendix Fig S1C), and
quantitative analysis confirmed that in the absence of Parkin,
MITOL-HA was retained on depolarized mitochondria (Fig 2B).
These results indicate that Parkin is required for MITOL relocation
from mitochondria to peroxisomes.
Next, we sought to demonstrate that pre-existing mitochondrial
MITOL moved to peroxisomes in response to mitochondrial depolar-
ization, rather than direct peroxisomal targeting of newly synthe-
sized MITOL following CCCP treatment. The simplest experiment
would suggest the use of cycloheximide (CHX), which blocks
protein synthesis. However, we cannot use CHX as Parkin transloca-
tion to impaired mitochondria depends on the accumulation of
newly synthesized PINK1 on the outer mitochondrial membrane
▸Figure 1. MITOL redistributes to peroxisomes in response to a loss in the mitochondrial membrane potential.A–C MITOL-HA formed small dot-like structures following CCCP treatment. HeLa cells transiently expressing Flag-Parkin and MITOL-HA were treated with 15 lM CCCP
for 3 h, and then subjected to immunocytochemistry. MITOL and Tom20 (mitochondrial marker; A) signals co-localized well without CCCP treatment, whereas the
MITOL-positive small dots were not coincident with Tom20, Sec61b (ER marker; B), or LAMP1 (lysosomal marker; C) after CCCP treatment. Scale bars, 10 lm.
D MITOL-HA co-localized with catalase (peroxisome marker) following CCCP treatment. Higher magnification images of the boxed regions are shown in the small
panel. Scale bars, 10 lm. Arrowheads indicate representative examples of MITOL-HA co-localization with catalase.
E Correlation statistics for the localization of MITOL-HA and Tom20, Sec61b, LAMP1, or catalase. Dots indicate individual Pearson correlation coefficient data points.
In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined in the R software package, and the
whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and X-axis,
respectively. Statistical significance was calculated using a one-tailed Welch’s t-test.
F The line graph shows a line scan of fluorescence through three MITOL-positive peroxisomes (red bar in D) that clearly indicates co-localization of MITOL (green
line) and catalase (magenta line).
G Peroxisomal membrane protein (PMP) 34-FusionRed also co-localized with MITOL-GFP in Parkin-expressing HeLa cells after 3 h of CCCP treatment. Higher
magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm.
H Correlation statistics for the localization of MITOL-GFP and PMP34-FusionRed. Dots indicate individual Pearson correlation coefficient data points. In the box-plots,
the center lines indicate the medians, box limits indicate the 25th and 75th percentiles as determined in the R software package, and the whiskers extend 1.5 times
the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and X-axis, respectively. Statistical significance
was calculated using a one-tailed Welch’s t-test.
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Co-localization of MITOL-GFP and PMP34-FusionRed

































HeLa cells transiently expressing Flag-Parkin
Figure 1.
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following CCCP treatment, and thus, CHX treatment would block
PINK1 synthesis and consequently impede Parkin translocation/
activation [39]. Instead of CHX, we utilized a doxycycline induction/
repression system. HeLa cells stably expressing HA-Parkin were
transiently transfected with pTRE3G-3Flag-MITOL and pCMV-Tet3G
plasmids. Before doxycycline treatment, MITOL expression was
repressed and no signal was observed (Fig 2F, top panel). After 3 h
of doxycycline treatment, MITOL expression was induced and the
protein localized on mitochondria (Fig 2F). Cells were then repeat-
edly washed to remove doxycycline induction (i.e., no new MITOL
synthesis) and treated with CCCP for an additional 3 h. Examination
of these cells revealed co-localization of MITOL and the peroxisomal
marker Pex14 (Fig 2F), suggesting that previously synthesized
MITOL that had been localized on mitochondria had moved to
peroxisomes in response to CCCP treatment.
We also wanted to eliminate the trivial possibility that (i) MITOL
exists in two distinct organellar states, one that is predominantly
localized on mitochondria and a smaller grouping localized on
peroxisomes, and (ii) that very rapid degradation (within 3 h) of
mitochondria-localized MITOL leaves peroxisome-localized MITOL
as the dominant grouping. This possibility could lead to an erro-
neous conclusion that MITOL translocated to the peroxisomes. If
true, then the total amount of MITOL should decrease rapidly;
however, the protein level of MITOL was not drastically altered
following CCCP or MG132 treatment, suggesting that a large fraction
of MITOL is not rapidly degraded during mitophagy stimulation
(Fig 2C). Furthermore, we monitored the levels of MITOL over an
extended period of valinomycin treatment (6 and 24 h) in conjunc-
tion with fractionation analysis. Mitofusin2 (MFN2), which is
degraded by the proteasome following mitochondrial depolarization
[22], underwent rapid degradation within 3 h of valinomycin treat-
ment (Fig 2D and E), in particular the mitochondria-rich fractions.
MTCO2, an inner mitochondrial protein that is degraded via mito-
phagy following mitochondrial depolarization [40], was significantly
decreased following 24 h of valinomycin treatment (Fig 2D and E).
In contrast, 3Flag-MITOL persisted throughout the first 6 h and only
underwent a slight reduction after 24 h, confirming that the total
cellular amount of MITOL is not dramatically decreased. Although
MITOL underwent a modest reduction at 24 h, it was not as rapid as
that seen with MFN2 and MTCO2 that are destined for Ub- and
mitophagy-mediated degradation (Fig 2D and E). Given that the
mitochondria-enriched fraction contains some peroxisomes (as
shown in Fig 11), the results are consistent with our hypothesis that
mitochondrial MITOL is not degraded but rather migrates to peroxi-
somes.
MITOL redistribution from impaired mitochondria to peroxi-
somes occurs downstream of Parkin. Because ATG5 is indispensable
for the progression of autophagy, an ATG5 knockout cell line was
used to investigate whether mitophagy inhibition affects the peroxi-
somal translocation of MITOL. When MITOL localization in ATG5
knockout cells stably expressing HA-Parkin and 3Flag-MITOL was
analyzed by immunocytochemistry, MITOL clearly overlapped with
PMP70 (peroxisomal marker) following CCCP treatment, which was
similar to that seen in wild-type cells (Fig EV1). This indicates that
inhibition of mitophagy does not affect the redistribution of MITOL
to peroxisomes. These results further refute the possibility that
MITOL is localized on both peroxisomes and mitochondria under
steady-state conditions and that peroxisomal localization only
becomes apparent following the rapid degradation of mitochondrial
MITOL via CCCP-induced mitophagy.
Collectively, it is unlikely that newly synthesized MITOL is
directly targeted to peroxisomes in response to CCCP treatment or
that mitochondrial MITOL is rapidly degraded within 3 h of CCCP
treatment; rather, the data support translocation of pre-existing
mitochondrial MITOL to peroxisomes in response to mitochondrial
depolarization.
To further analyze Parkin dependency, we examined whether
Parkin E3 activity is required for MITOL translocation to peroxi-
somes. In the presence of wild-type Parkin, 3Flag-MITOL localized
to peroxisomes after CCCP treatment as described above. In
contrast, no MITOL translocation was observed in cells expressing a
Parkin (C431S) mutant in which the catalytic Cys critical for E3
activity had been mutated (Fig 3A, middle panels), indicating that
the redistribution of MITOL from mitochondria to peroxisomes
requires Parkin E3 activity. Furthermore, we also confirmed that
PINK1 is required for MITOL redistribution. In PINK1 knockout
◀ Figure 2. Parkin is required for MITOL redistribution to peroxisomes.A MITOL-HA did not move to peroxisomes, but was rather retained on mitochondria even after CCCP treatment in HeLa cells lacking endogenous Parkin. Wild-type
HeLa cells or HeLa cells stably expressing GFP-Parkin were transfected with MITOL-HA, treated with 15 lM CCCP for 3 h, and then subjected to
immunocytochemistry with anti-HA and anti-Tom20 antibodies. Higher magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm.
B Correlation statistics for the localization of MITOL-HA and Tom20 in the absence or presence of GFP-Parkin. Dots indicate individual Pearson correlation coefficient
data points. In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined in the R software package, and
the whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and X-axis,
respectively. Statistical significance was calculated using a one-tailed Welch’s t-test.
C MITOL was not degraded following mitochondrial depolarization. HeLa cells stably expressing 3Flag-MITOL were transfected with a GFP-Parkin plasmid or the
pEGFP-C1 vector, treated with 15 lM CCCP  10 lM MG132 for 3 h, and then immunoblotted with anti-Flag, anti-ubiquitin, and anti-tubulin antibodies. Black
arrowheads indicate 3Flag-MITOL in the upper panel and mono-ubiquitin in the middle panel, respectively.
D The total cellular amount of MITOL was not dramatically reduced following extended valinomycin treatment. Immunoblotting combined with fractionation analysis
showed that mitofusin2 (MFN2) underwent rapid degradation within 3 h of valinomycin treatment, in particular in the 3,000 g pellet (mitochondria-rich fractions).
Cytochrome c oxidase subunit 2 (MTCO2, inner mitochondrial protein) was significantly reduced at 24 h 10 lM valinomycin treatment. In contrast to those two
proteins, MITOL degradation was minimal. Note that the chemical apoptosis inhibitor Z-VAD-FMK (10 lM) was added to cells along with valinomycin to prevent cell
death.
E Quantification of 3Flag-MITOL, MFN2, and MTCO2 protein levels in the PNS and 3,000 g pellet fraction following 10 lM valinomycin + Z-VAD-FMK treatment at the
indicated times. Data represent the mean fold change  s.e.m. relative to untreated samples in three biological replicates.
F Pre-existing MITOL on mitochondria moves to peroxisomes following CCCP treatment. Following doxycycline treatment for 3 h to induce MITOL expression, cells were
washed with fresh medium to stop the synthesis of new MITOL. After treatment with or without CCCP for more than 3 h, cells were immunostained using anti-Flag,
anti-Pex14 (peroxisomal membrane protein), and anti-Hsp60 antibodies. Higher magnification images of the boxed regions are shown in the bottom panel. Scale
bars, 10 lm.
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(KO) HeLa cells [41], the redistribution of MITOL to peroxisomes
was not observed when mitochondria were damaged despite the
presence of wild-type Parkin (Fig 3A, lower panel). These results
were further substantiated by quantitative analysis (Fig 3C). To
determine whether endogenous levels of Parkin are sufficient for
the transition of MITOL from damaged mitochondria to peroxi-
somes, we utilized an SH-SY5Y human neuroblastoma cell line
that expresses endogenous Parkin. SH-SY5Y cells transiently
expressing 3Flag-MITOL were treated with valinomycin + Z-VAD-
FMK for 3 or 6 h and then analyzed by immunofluorescence (note
that Z-VAD-FMK is an apoptosis inhibitor that was included in the
incubation because SH-SY5Y cells are more sensitive to uncoupler
treatment and detach easily). As shown in Appendix Fig S3,
MITOL once again redistributed to peroxisomes. However, the
frequency of MITOL redistribution in SH-SY5Y cells appeared to be
lower than that observed following overexpression in HeLa cells.
We think this difference arises from the experimental conditions.
Typically, only a minor population of mitochondria are damaged,
and thus, the physiological levels of Parkin are sufficient to
manage them. However, valinomycin or CCCP treatment causes
depolarization of all mitochondria, and as a result, the endogenous
levels of Parkin are overwhelmed. Given that the endogenous
levels of Parkin in SH-SY5Y cell lines are lower than in the overex-
pression conditions, the endogenous Parkin might be insufficient
to assist in relocation of all the MITOL molecules from damaged
mitochondria to peroxisomes. However, we do observe peroxiso-
mal localization of MITOL without exogenous Parkin expression.
We thus conclude that in addition to mitochondrial membrane
dissipation, both PINK1 and the E3 activity of Parkin are essential
for the translocation of MITOL to peroxisomes.
MITOL specifically relocates to peroxisomes
Since MITOL is an E3, we next examined whether the E3 activity of
MITOL itself is required for translocation to peroxisomes. To impair
the MITOL E3 activity, we mutated Cys65/Cys68 within the RING
domain of MITOL to Ser (CS) or the conserved Zn-binding His43 to
Trp (H43W) [34,35]. Despite higher background peroxisomal signals,
MITOL CS and H43W mutants localize on mitochondria. However,
following 3 h of CCCP treatment, both mutants clearly co-localized
with catalase (Fig 3B). Quantitative analysis confirmed the cytochem-
ical results (Fig 3D), indicating that the redistribution of MITOL from
mitochondria to peroxisomes does not require its own E3 activity.
Next, to determine whether the Parkin-dependent translocation
from depolarized mitochondria to peroxisomes is limited to MITOL,
the localization of other mitochondrial proteins was analyzed by
immunostaining. The proteins examined included both N-terminal
anchored proteins, MitoNEET/CISD1 and Tom70, and C-terminal
anchored proteins Fis1 and Miro1/2 (Fig 4A). No peroxisomal
translocation following CCCP treatment was observed for either
N-terminal anchored or C-terminal anchored proteins (Fig 4B). The
matrix protein, Hsp60, likewise did not undergo peroxisomal
translocation following CCCP treatment (Fig 4B). It has been
reported that Drp1, Fis1, Mitofusin (MFN) 1/2, MiD49, and Mcl1
interact with MITOL as substrates [33,34,42–44]. We consequently
also examined the subcellular localization of these proteins follow-
ing CCCP treatment. Because antibodies that detect endogenous
MFN2, MiD49, and Mcl1 were not available, we constructed tagged
plasmids. We found that none of the proteins [i.e., Drp1 (Fig EV2A),
MFN1 (Fig EV2E), MFN2 (Fig EV2B), Mcl1 (Fig EV2C), and MiD49
(Fig EV2D)] was predominantly localized to peroxisomes following
◀ Figure 3. Both PINK1 and the E3 activity of Parkin are required for MITOL redistribution to peroxisomes.A Wild-type or PINK1 knockout (KO) HeLa cells were transfected with GFP-Parkin wild-type or the C431S mutant, treated with 15 lM CCCP, and then immunostained
with anti-Flag and anti-catalase antibodies. Wild-type Parkin, but not the catalytically inactive Parkin (C431S) mutant, mediated 3Flag-MITOL translocation to
peroxisomes following mitophagy stimulation. In PINK1 KO HeLa cells, the redistribution of MITOL to peroxisomes was not observed even in the presence of wild-type
Parkin when mitochondria were damaged. Higher magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm. Arrowheads indicate
representative examples of MITOL–peroxisome co-localization observed only in the presence of wild-type Parkin.
B The redistribution of MITOL from mitochondria to peroxisomes does not require its own E3 activity. The E3-inactive MITOL Cys65Ser/Cys68Ser (CS) and H43W
mutants were transfected into HeLa cells stably expressing HA-Parkin, treated with 15 lM CCCP, and then subjected to immunocytochemistry with anti-Flag and
anti-catalase antibodies. After 3 h of CCCP treatment, both the CS and H43W mutants co-localized with catalase. Higher magnification images of the boxed regions
are shown in the small panel. Scale bars, 10 lm. Arrowheads indicate representative examples of 3Flag-MITOL co-localization with catalase.
C Correlation statistics for the localization of 3Flag-MITOL and catalase in the presence of GFP-Parkin wild-type or an inactive C431S mutant. Dots indicate individual
Pearson correlation coefficient data points. In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined
in the R software package, and the whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown
on the box and X-axis, respectively. Statistical significance was calculated using a one-tailed Welch’s t-test. MITOL overlapped with catalase only in the presence of
wild-type Parkin in wild-type HeLa cells. In PINK1 knockout (KO) HeLa cells, wild-type Parkin was unable to induce the peroxisomal translocation of MITOL.
D Correlation statistics for the localization of 3Flag-MITOL wild-type or inactive mutants with catalase. Dots indicate individual Pearson correlation coefficient data
points. In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined in the R software package, and the
whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and X-axis, respectively.
Statistical significance was calculated using a one-tailed Welch’s t-test.
▸Figure 4. MITOL specifically relocates to peroxisomes.A Schematic topology representation of the mitochondrial membrane proteins analyzed in this study.
B Peroxisomal translocation of other mitochondrial proteins such as MitoNEET/CISD1, Fis1, Miro1/2, and Tom70 (mitochondrial outer membrane proteins), and Hsp60
(mitochondrial matrix protein) was not observed in CCCP-treated cells. HeLa cells stably expressing HA-Parkin were treated with 15 lM CCCP for 3 h, and then
immunostained with anti-MitoNEET/CISD1, anti-Fis1, anti-Miro1/2, anti-Tom70, anti-Hsp60, and anti-catalase antibodies. Scale bars, 10 lm.
C A multi-spanning outer membrane protein PBR (peripheral benzodiazepine receptor) did not co-localize with catalase, but did with Tom20 during mitophagy. HeLa
cells stably expressing HA-Parkin were treated with 15 lM CCCP for 3 h, and then immunostained with anti-Flag, anti-Tom20, and anti-catalase antibodies. Scale
bars, 10 lm.
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CCCP treatment for 3 h, indicating that mitochondrial proteins other
than MITOL do not relocate to peroxisomes.
As MITOL has four transmembrane domains, we also examined
whether translocation to peroxisomes is a common phenomenon of
mitochondrial proteins with multiple transmembrane domains. PBR
(peripheral benzodiazepine receptor) is a multi-spanning outer
membrane protein with five transmembrane domains that imports
cholesterol to the inner membrane (Fig 4A) [45]. Overexpressed
PBR-3Flag localized on mitochondria but did not undergo CCCP-
induced translocation to peroxisomes (Fig 4C). Based on these
immunocytochemical observations, the redistribution from mito-
chondria to peroxisomes is specific to MITOL.
MITOL is targeted to mitochondria via Tom70 and is then
delivered to peroxisomes
Next, we sought to elucidate the mechanism underlying the peroxiso-
mal targeting of MITOL. Does newly synthesized MITOL have the
ability to directly integrate into the peroxisomal membrane when it
fails to target to mitochondria? To examine this, siRNAs targeting
several subunits of the mitochondrial outer membrane translocator
(Tom70, Tom20, Tom40, and Sam50) were transfected into HeLa
cells twice within a 24-h interval. At 72 h post-transfection, the cells
were re-transfected with 3Flag-MITOL and Su9-GFP (the targeting
sequence of the FoF1 ATPase subunit 9; a model precursor protein
that targets to the matrix). Cells were then subjected to immunostain-
ing 16 h post-plasmid transfection. Tom70, Tom20, Tom40, and
Sam50 were all efficiently knocked down (Fig 5A). As expected,
Su9-GFP (positive control for canonical Tom20/Tom40-dependent
transport) was not imported into the mitochondria, but rather local-
ized to the cytosol and nucleus when Tom20 and Tom40 were
knocked down (Fig 5B). In these Tom20- and Tom40-knockdown
cells, however, 3Flag-MITOL localized to mitochondria. Although
Sam50 siRNA affected cell viability, 3Flag-MITOL was still localized
to mitochondria. In contrast, when Tom70was knocked down, 3Flag-
MITOL did not localize to mitochondria, instead it was dispersed in
the cytosol (Fig 5B). Consistent with this, PBR integration into the
mitochondrial outer membrane was previously reported to be
Tom70-dependent [45]. For statistical analysis, the number of HeLa
cells exhibiting cytosolic localization of Su9-GFP or 3Flag-MITOL in
each siRNA experiment was determined; a finding that confirmed the
earlier results (Fig 5C). The immunocytochemistry-based cytosolic
localization signal of MITOL in Tom70-knockdown cells was weak
(Fig 5B), an effect that we surmise was the result of limited epitope
accessibility under the immunocytochemical conditions when MITOL
is released into the cytosol. However, to demonstrate cytosolic local-
ization of MITOL biochemically, we also tried subcellular fractiona-
tion. Although a significant percentage of MITOL detaches from
mitochondria during the fractionation process, a sufficient amount of
MITOL was retained in the mitochondria-enriched fraction in control
cells (Fig 5D, lanes 2 and 3). In contrast, almost all of the MITOL was
collected in the cytosolic fraction in siTom70-treated cells with no
detectable signal in the mitochondria-enriched fraction (Fig 5D, lanes
5 and 6). This result further underscores that MITOL is dispersed to
the cytosol when cellular levels of Tom70 are decreased. Importantly,
MITOL in the Tom70-knockdown cells did not co-localize with cata-
lase, indicating that the MITOL precursor, which was not targeted to
the mitochondria, was unable to integrate into the peroxisomal
membranes. This means that translocation of MITOL from mitochon-
dria to peroxisomes occurs via a Parkin-mediated mitochondrial
quality control pathway.
MITOL is retained on mitochondria in peroxisome-null cells
To examine mitophagy-induced MITOL localization in the absence of
peroxisomes, we genetically generated peroxisome-depleted cells.
Pex19 is essential for forming and maintaining peroxisomes [46]. To
generate peroxisome-null cell lines, we used the CRISPR/Cas9 gene
editing system to knock out PEX19 (Appendix Fig S4A). We first con-
firmed peroxisomal loss by verifying that the catalase signal in the
PEX19 knockout HCT116 cell line was localized to the cytosol as
reported previously (Fig 6A)[46,47]. Wild-type and PEX19 knockout
HCT116 cells stably expressing HA-Parkin and 3Flag-MITOL were
then immunostained with anti-Flag, anti-catalase, anti-Hsp60, and
anti-Tom20 antibodies. In wild-type HCT116 cells, MITOL transloca-
tion from mitochondria to peroxisomes proceeded as expected in
response to mitochondrial depolarization (Fig 6B and C). In PEX19
knockout cells, however, MITOL remained localized on mitochondria
after valinomycin treatment (Fig 6B and C, and Appendix Fig S4B).
Peroxins mediate MITOL translocation
The above results prompted us to further analyze the molecular
basis of MITOL redistribution to peroxisomes. In PEX19 knockout
▸Figure 5. MITOL is targeted to mitochondria via Tom70 and is then delivered to peroxisomes.A siRNA-based knockdown of endogenous Tom70, Tom20, Tom40, and Sam50. HeLa cells treated with the corresponding siRNAs and immunoblotted with the indicated
antibodies. AIF, apoptosis-inducing factor.
B HeLa cells were immunostained with anti-Flag and anti-catalase antibodies after treatment of each siRNA. Tom20- and Tom40-siRNA treatment inhibited import of
Su9-GFP (the targeting sequence of the FoF1 ATPase subunit 9) into the mitochondria, leading to an accumulation of Su9-GFP precursor proteins in the cytosol and
cell nucleus. 3Flag-MITOL still localized to mitochondria in Tom20, Tom40, and Sam50 siRNA-treated cells. In contrast, 3Flag-MITOL dispersed into the cytosol when
Tom70 was knocked down. Scale bars, 10 lm.
C Statistical analysis of the MITOL subcellular localization following 15 lM CCCP treatment for 3 h in cells treated with control, Tom70, Tom20, Tom40, or Sam50
siRNAs. Su9-GFP was not imported into the mitochondria, but rather localized to the cytosol and nucleus following Tom20 and Tom40 knockdown. The number of
HeLa cells with cytosol-localized Su9-GFP or 3Flag-MITOL in each siRNA experiment was determined. Data represent the mean  s.e.m. from > 100 cells in three
biological replicates. (In case of Tom40, and Sam50 siRNAs, data represent the mean  s.e.m. from > 60 cells in three biological replicates.) Statistical significance
was calculated using a one-tailed Welch’s t-test.
D HeLa cells treated with siControl or siTom70 were fractionated into cytosolic and mitochondrial fractions and then immunoblotted with anti-lactate dehydrogenase
(LDH), anti-Tom20, and anti-Flag antibodies. LDH was used as a cytosolic marker. Although some MITOL detached from mitochondria during fractionation, sufficient
amounts of MITOL were collected in the mitochondria-enriched fraction in control cells. In contrast, almost all of the MITOL was collected in the cytosolic fraction in
siTom70-treated cells.
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cells, peroxisomes were lost and thus the catalase-positive dot-like
signal disappeared (Fig 6A). Under these conditions, even if MITOL
is retained on mitochondria (Fig 6C), it is difficult to interpret
whether Pex19 is important for MITOL translocation to peroxisomes
or whether the mitochondrial localization of MITOL is attributable to
the loss of the final destination peroxisomes. To better address this
question, we performed knockdown experiments, which resulted in
peroxisomal retention and an observable catalase signal (Fig 7C). In
mammalian cells, the targeting of newly synthesized peroxisomal
membrane proteins utilizes either a Pex19/Pex3 (class I pathway) or
Pex19/Pex16 (class II pathway) [48–50]. Pex3 on the peroxisomal
membrane functions as a receptor for cytosolic Pex19, which associ-
ates with a newly synthesized substrate (class I pathway). On the
other hand, targeting of newly synthesized Pex3 to peroxisomes
requires Pex19 and Pex16 (class II pathway). To understand which
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localization in cells transfected with PEX3, PEX16, or PEX19 siRNAs.
We confirmed that Pex3, Pex16, and Pex19 were reduced in the
corresponding siRNA-treated cells (Fig 7A), and MITOL amounts
were not affected in PEX3-, PEX16-, and PEX19-knockdown cells
(Fig 7B). siRNA-mediated knockdown of PEX3, PEX16, or PEX19 had
no effect on MITOL mitochondrial integration under steady-state
conditions. Importantly, however, knockdown of PEX3, PEX16, or
PEX19 impaired translocation of MITOL to peroxisomes following
CCCP treatment (Fig 7C). Quantification analysis of co-localization
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B HCT116 cells stably expressing HA-Parkin and 3Flag-MITOL
PEX19 -/- HCT116 clone #4 cells stably expressing HA-Parkin and 3Flag-MITOL
Catalase
Catalase
Figure 6. MITOL retained on mitochondria in peroxisome-null cells.
A CRISPR/Cas9 gene editing was used to generate peroxisome-null cell lines by knocking out PEX19. In wild-type HCT116 cells, catalase localized to peroxisomes (dot-
like structures), whereas in PEX19/ cells catalase was diffusely localized throughout the cytosol, indicating loss of peroxisomes. Scale bars, 10 lm.
B, C Wild-type and PEX19/ HCT116 cells stably expressing HA-Parkin and 3Flag-MITOL were treated with 10 lM valinomycin for 3 h, and then subjected to
immunocytochemistry with anti-Flag, anti-catalase, and anti-Hsp60 (B), or anti-Flag and anti-Tom20 (C) antibodies. In wild-type HCT116 cells, MITOL translocated
to peroxisomes, whereas MITOL remained associated with mitochondria in PEX19/ cells. Arrowheads indicate representative examples of 3Flag-MITOL co-
localization with catalase rather than Hsp60 in wild-type HCT116 cells.
Data information: Higher magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm.
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coefficients revealed that the peroxisomal translocation of MITOL in
control siRNA cells (Fig 7D, columns 1 and 2) was decreased in
siPEX3- and siPEX16-treated cells with PEX3 knockdown having the
most pronounced inhibitory effects (Fig 7D, columns 3 and 4).
Indeed, in siPEX3-treated cells, no significant difference (P = 0.16) in
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between CCCP-treated and untreated conditions. In PEX19-silenced
cells, the co-localization between MITOL and catalase was slightly
impaired, but co-localization of 3Flag-MITOL and catalase was signif-
icantly increased in CCCP-treated cells (Fig 7D, columns 7 and 8).
These results indicate that MITOL translocation from mitochondria
to peroxisomes depends on Pex3 activity.
MITOL is extracted from mitochondria in a p97/VCP ATPase-
dependent manner
Since MITOL is a multi-spanning protein, we hypothesized that
MITOL is selectively extracted from the mitochondrial outer
membrane following mitophagy stimulation. To address this, we
focused on p97/VCP. p97/VCP is a well-conserved abundant
hexameric ring-shaped AAA+-ATPase that, with differing cofactors,
functions in multiple cellular events such as proteasome-dependent
protein degradation, membrane fusion, trafficking, autophagy, and
genomic DNA surveillance [51,52]. Since p97/VCP is required for
proteasomal degradation of the mitochondrial outer membrane
proteins mitofusin1 and mitofusin2 following Parkin-mediated ubiq-
uitylation [22], p97/VCP might also play a role in the mitochondrial
extraction of MITOL. We first knocked down p97/VCP and exam-
ined the subcellular localization of MITOL. In control cells, CCCP-
dependent co-localization of MITOL and catalase was observed,
whereas in p97/VCP knockdown cells MITOL predominantly over-
lapped with Hsp60 (Fig 8A and B). Because of cell viability issues,
however, complete p97/VCP depletion was not achieved. Therefore,
to obtain more robust data, we used p97/VCP ATPase mutants and
an allosteric chemical inhibitor. Overexpression of p97/VCP E305Q/
E578Q (p97QQ), which is known to have a dominant-negative effect
[53], inhibited MITOL redistribution from mitochondria to peroxi-
somes, while overexpression of wild-type p97/VCP did not suppress
MITOL redistribution (Fig 8C). Furthermore, in the presence of the
specific p97/VCP inhibitor NMS-873, mitochondrial depolarization-
induced MITOL translocation was blocked (Fig 8D). Quantification
analysis confirmed that the translocation of MITOL to peroxisomes
was completely inhibited by the specific p97/VCP inhibitor NMS-
873 (Fig 8E). These results revealed that MITOL is extracted from
mitochondria in a p97/VCP ATPase-dependent manner.
Ubiquitylation of C-terminal K268 is required for MITOL
relocation to peroxisomes
We have shown that the translocation of MITOL to peroxisomes
depends on Parkin, a decrease in mitochondrial membrane poten-
tial, and p97/VCP. We next examined whether Parkin-mediated
ubiquitylation of MITOL is essential for translocation. To detect
MITOL ubiquitylation, total cell lysates from HeLa cells stably
expressing HA-Parkin and 3Flag-MITOL after CCCP treatment were
immunoblotted with an anti-Flag antibody. Initially, a ubiquityla-
tion-derived molecular weight shift of MITOL was not observed
clearly (Fig EV3A, lanes 1 and 2). However, it is possible that the
ubiquitylation of MITOL that occurs during mitochondrial localiza-
tion is removed following translocation to peroxisomes. We thus
added NMS-873 (p97/VCP inhibitor used in Fig 8D) to retain MITOL
on the depolarized mitochondria, and observed a ubiquitylation-like
◀ Figure 7. MITOL translocation to peroxisomes is mediated by peroxins.A siRNA-based knockdown of Pex3, Pex16, and Pex19. HeLa cell lysates treated with the indicated plasmids and siRNAs were immunoblotted with the indicated
antibodies.
B A comparable amount of MITOL was detected in control, PEX3-, PEX16-, and PEX19-knockdown cells. HeLa cell lysates stably expressing HA-Parkin and 3Flag-MITOL
treated with the corresponding siRNAs were immunoblotted with the indicated antibodies.
C MITOL translocation from the mitochondria to peroxisomes is highly dependent on Pex3. HeLa cells stably expressing 3Flag-MITOL and HA-Parkin were transfected
with control, PEX3, PEX16, or PEX19 siRNA, treated with 15 lM CCCP for 3 h, and then subjected to immunocytochemistry with anti-Flag and anti-catalase antibodies.
Scale bars, 10 lm.
D Correlation statistics for the localization of 3Flag-MITOL and catalase in cells transfected with the indicated siRNAs. Dots indicate individual Pearson correlation
coefficient data points. In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined in the R software
package, and the whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and
X-axis, respectively. Statistical significance was calculated using a one-tailed Welch’s t-test.
▸Figure 8. MITOL is extracted from mitochondria in a p97/VCP ATPase-dependent manner.A MITOL did not merge with Hsp60 in control siRNA-treated cells, whereas most MITOL co-localized with Hsp60 in p97/VCP knockdown cells in response to mitophagy
stimuli. HeLa cells stably expressing 3Flag-MITOL and HA-Parkin were transfected with control or p97/VCP siRNA, treated with 15 lM CCCP for 3 h, and then
subjected to immunocytochemistry with anti-Flag, anti-catalase, and anti-Hsp60 antibodies. Scale bars, 10 lm.
B HeLa cell lysates treated with control or p97/VCP siRNA were immunoblotted with anti-p97/VCP and anti-tubulin antibodies.
C Overexpression of a p97/VCP ATP hydrolysis-defective mutant, E305Q/E578Q (p97QQ), blocked MITOL redistribution from mitochondria to peroxisomes, while
overexpression of wild-type p97/VCP had no effect on MITOL redistribution. HeLa cells stably expressing GFP-Parkin were transfected with MITOL-HA and Flag-p97/
VCP wild-type or p97QQ, treated with 15 lM CCCP for 3 h, and then subjected to immunocytochemistry with anti-HA and anti-catalase antibodies. Higher
magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm.
D NMS-873, a specific inhibitor of p97/VCP, prevented MITOL translocation following CCCP treatment. HeLa cells stably expressing HA-Parkin were transfected with
3Flag-MITOL, treated with 15 lM CCCP in the presence or absence of 10 lM NMS-873 for 3 h, and then subjected to immunostaining with anti-Flag, anti-catalase,
and anti-HA antibodies. Higher magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm. Arrowheads in (C) and (D) indicate
representative examples of MITOL–peroxisome co-localization that was only observed in the presence of a functional VCP.
E Correlation statistics for the localization of 3Flag-MITOL and catalase in the presence of NMS-873. Dots indicate individual Pearson correlation coefficient data points.
In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined in the R software package, and the
whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and X-axis, respectively.
Statistical significance was calculated using a one-tailed Welch’s t-test.
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molecular weight shift of 3Flag-MITOL (Fig EV3A, lanes 3 and 4).
HeLa cells stably expressing 3Flag-MITOL were immunoprecipitated
with an anti-Flag antibody and then immunoblotted with anti-Flag
and anti-ubiquitin antibodies. Although MITOL was ubiquitylated
following CCCP and NMS-873 treatment in Parkin-expressing cells
(Fig 9A, lanes 3 and 4), no ubiquitylation signal was observed in
wild-type HeLa cells lacking endogenous Parkin under the same
experimental conditions (Fig 9A, lanes 1 and 2). This result con-
firms that Parkin ubiquitylates MITOL in response to a decrease in
the mitochondrial membrane potential.
As indicated previously, clear ubiquitylation was observed
following CCCP and NMS-873 treatment (Fig EV3), suggesting that
the MITOL ubiquitylation that is mediated on depolarized mitochon-
dria is removed on peroxisomes. It is thus of interest whether
MITOL needs to be de-ubiquitylated for peroxisomal localization.
Given that the de-ubiquitylating enzyme USP30 localizes to both
mitochondria and peroxisomes and is involved in Parkin-mediated
mitophagy [54–57], we examined whether USP30 also contributes
to MITOL translocation. The ubiquitylation status of MITOL in
USP30 knockout HeLa cells (Appendix Fig S5, lanes 4–9) was almost
identical to that in wild-type HeLa cells (Appendix Fig S5, lanes 1–
3). In addition, following CCCP treatment for 1.5 and 3 h, MITOL
translocated equally from mitochondria to peroxisomes in both
wild-type and USP30 knockout HeLa cell (Appendix Fig S6). These
results suggest that at least USP30-catalyzed de-ubiquitylation is not
involved in MITOL translocation.
We next tried to determine the ubiquitylation site of MITOL.
Using an LC-MS/MS-based analysis, we identified K40, K54, and
K268 as ubiquitin modified sites in the MITOL sequence following
valinomycin treatment (Fig EV3B). To examine whether these ubiq-
uitylations are required for MITOL translocation, MITOL K268 was
mutated to Ala. The K268A mutant targeted to mitochondria under
steady-state conditions, but translocation to peroxisomes upon
CCCP treatment was disturbed (Fig 9C). Because the K-to-A muta-
tion not only inhibits ubiquitylation but also changes the charge
and bulkiness of the amino acid side chain, we also examined the
effect of a K268R mutation that maintains both properties, but that
hampers ubiquitylation. Immunocytochemical analysis showed that
neither the K268A nor the K268R mutant translocated to peroxi-
somes (Fig 9C), a conclusion that was supported by quantitative
analyses (Fig 9E). These results suggest that ubiquitylation of K268
is important for Parkin-induced redistribution of MITOL to peroxi-
somes. Since mass spectrometry analysis revealed that K40 and K54
in the RING domain were also ubiquitylated in response to mito-
phagy, we made similar mutations to K40 and K54. Translocation
of MITOL to peroxisomes was slightly impeded by the K54A and
K54R mutations (Fig EV4), although the effect was weaker than
that seen with the K268A and K268R mutations. The K40A and
K40R mutations had little effect on peroxisomal redistribution of
MITOL following CCCP treatment (Fig EV4). A combination of the
K54 and K268 mutations failed to generate results that differed
significantly from the K268 mutation alone (Fig 9D). While clear
ubiquitylation of wild-type MITOL was observed following CCCP
and NMS-873 treatment (Fig 9B, lanes 1 and 2), immunoprecipita-
tion analysis revealed that the ubiquitylation ladder was not formed
on the MITOL K268A and K54A/K268A mutants (Fig 9B, lanes 3–
6). The Lys residue at this position (268 in humans) is well
conserved from mammals to zebra fish, suggesting its physiological
importance (Fig EV3D). LC-MS/MS-based analysis showed that the
abundance ratio of K268 ubiquitylation in valinomycin-treated
samples was about 28 times higher than in non-treated control
samples (Figs 9F and EV3C); this ratio was less pronounced at K40
and K54. Taken together, these data indicate that the peroxisomal
targeting of MITOL from damaged mitochondria requires Parkin-
mediated ubiquitylation of K268 as a post-translational modifi-
cation.
We next investigated whether the translocation-defective mutant
of MITOL represses mitophagy progression or not. To quantify mito-
phagy by flow cytometry, we utilized HCT116 cells stably express-
ing both Parkin and the mitochondria-localized pH-dependent
fluorescent protein mt-Keima, which has a short excitation wave-
length under neutral conditions (e.g., in mitochondria) and under-
goes a shift to longer excitation wavelengths under acidic conditions
(e.g., in lysosomes) [58]. Consequently, mitophagy progression can
be monitored as a proportion of cells in which mt-Keima has under-
gone an acidification-specific fluorescence change. We then
compared the mitophagy activity of MITOL knockout HCT116 cells
complemented with wild-type MITOL (which can translocate to
peroxisomes) and MITOL knockout cells complemented with the
K268A MITOL mutant (which is defective in peroxisomal
▸Figure 9. Ubiquitylation of K268 in the MITOL C-terminus is required for relocation to peroxisomes.A MITOL was ubiquitylated only in the presence of Parkin when the mitochondrial membrane was decreased. After 15 lM CCCP treatment for 3 h, HeLa cells stably
expressing HA-Parkin and 3Flag-MITOL were immunoprecipitated with anti-Flag magnetic beads, and then immunoblotted with the indicated antibodies. Red bars
indicate ubiquitylation; the black arrowhead indicates 3Flag-MITOL.
B The characteristic ubiquitylation ladder was observed for wild-type MITOL, but was absent in the K268A and K54A/K268A mutants. Black arrowhead indicates 3Flag-
MITOL.
C The MITOL K268A and K268R mutants were targeted to mitochondria under steady-state conditions, whereas peroxisomal localization following CCCP treatment was
considerably disrupted. HeLa cells stably expressing HA-Parkin were transfected with 3Flag-MITOL wild-type, K268A, or K268R mutants, treated with 15 lM CCCP for
3 h, and then subjected to immunostaining with anti-Flag and anti-catalase antibodies. Scale bars, 10 lm.
D The double K54/K268 mutation did not change the MITOL localization pattern. The subcellular localization of the MITOL K268A or K268R mutants was not drastically
changed by inclusion of the K54A or K54R mutations. Scale bars, 10 lm.
E Correlation statistics for the localization of 3Flag-MITOL wild-type, K268A, or K268R mutants with catalase. Dots indicate individual Pearson correlation coefficient
data points. In the box-plots, the center lines indicate the medians, the box limits indicate the 25th and 75th percentiles as determined in the R software package, and
the whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and X-axis,
respectively. Statistical significance was calculated using a one-tailed Welch’s t-test.
F The fold change in ubiquitylation of MITOL K268, K40, and K54 in valinomycin-treated samples versus untreated samples. After 3 h of valinomycin treatment,
PEX19/ HCT116 cells stably expressing HA-Parkin and 3Flag-MITOL were immunoprecipitated with anti-Flag magnetic beads, and then subjected to LC-MS/MS
analysis for label-free quantification of ubiquitylated peptides. Error bars represent the mean  s.e.m. in three biological replicates.
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translocation). The mitophagic flux in ΔMITOL cells complemented
with MITOL K268A was equivalent to that in ΔMITOL cells comple-
mented with wild-type MITOL, suggesting that the retention of
MITOL on depolarized mitochondria does not inhibit mitophagy
progression itself (Fig EV5A and B).
Endogenous MITOL translocates to peroxisomes
Since the redistribution of MITOL was observed under overex-
pressed conditions, we next sought to confirm whether endogenous
MITOL also displayed peroxisomal localization in response to mito-
chondrial depolarization. However, specific antibodies suitable for
immunocytochemical detection of endogenous MITOL are not avail-
able. To address this issue, we established a MITOL-3Flag knock-in
(KI) cell line. Neomycin- or hygromycin-resistant markers including
3xFlag gene cassettes and the short homologous arms were inserted
upstream of the MITOL stop codon by CRISPR/Cas9-based genome
editing ([59] and see Materials and Methods for details). G418 and
hygromycin B-resistant single clones were isolated and the appropri-
ate 3Flag-tag insertion was verified by immunoblotting with an anti-
Flag antibody (Fig 10A). We observed MITOL subcellular localiza-
tion in MITOL-3Flag KI HCT116 cells stably expressing HA-Parkin
using anti-Flag, anti-catalase, and anti-Hsp60 antibodies. 3Flag-
tagged endogenous MITOL co-localized with Hsp60 under
steady-state conditions, whereas valinomycin treatment induced
translocation of 3Flag-tagged endogenous MITOL from mitochondria
to peroxisomes (Fig 10B) similar to that observed with overex-
pressed MITOL. Quantitative analysis confirmed that co-localization
of endogenous MITOL and catalase increased significantly in
response to mitophagy stimulation, although a small percentage of
3Flag-tagged endogenous MITOL localized on peroxisomes prior to
valinomycin treatment (Fig 10C). The collected data indicate that
endogenous MITOL also redistributes from mitochondria to peroxi-
somes in response to mitochondrial depolarization.
In Fig 8D, we showed that translocation of exogenous MITOL to
peroxisomes was blocked by the VCP inhibitor, NMS-873. We next
examined whether cells harboring 3Flag-tagged endogenous MITOL
would yield similar results. When MITOL-3Flag KI HCT116 cells
stably expressing HA-Parkin were treated with valinomycin for 3 h,
3Flag-tagged endogenous MITOL overlapped with PMP70 (peroxiso-
mal membrane protein 70). In contrast, the combined 3Flag-tagged
endogenous MITOL did not redistribute to peroxisomes following
the administration of NMS-873 and valinomycin (Fig 10D and E).
As shown in Fig 9A and B, exogenous MITOL is ubiquitylated prior
to peroxisomal translocation. We thus sought to determine whether
endogenous MITOL was ubiquitylated as well. MITOL-3Flag KI
HCT116 cells stably expressing HA-Parkin were treated with valino-
mycin and NMS-873 for 3 h, immunoprecipitated using anti-Flag
magnetic beads, and immunoblotted using anti-Flag and anti-
ubiquitin antibodies. The immunoblots indicate that 3Flag-tagged
endogenous MITOL is also ubiquitylated in response to a loss in the
mitochondrial membrane potential (Fig 10F). These data confirm
that key aspects of the MITOL translocation pathway (i.e., VCP- and
ubiquitin-dependent translocation from depolarized mitochondria to
peroxisomes) are relevant for both overexpressed and endogenous
MITOL.
MITOL levels in peroxisome-enriched cellular subfractions are
increased following mitochondrial depolarization
To quantify the subcellular localization of MITOL, high-speed frac-
tionation of cultured cells was performed. Although initially chal-
lenging (similar densities between mitochondria and peroxisomes
and methodology-based detachment of MITOL), useful fractions
were obtained by adding NMS-873 (VCP inhibitor) to the lysis buffer
and subjecting the resultant lysates to a multi-step centrifugation
process. The post-nuclear supernatant (PNS) collected from HCT116
cells stably expressing HA-Parkin and 3Flag-MITOL was centrifuged
at 3,000 g to obtain a “3,000 g pellet” fraction with the resulting
supernatant further centrifuged at 100,000 g to yield a “100,000 g
pellet” fraction. Mitochondria were recovered in the 3,000 g pellet,
whereas the 100,000 g pellet was almost free of mitochondria
(Fig 11A, Tom20 signal of lanes 2 and 3). Peroxisomes were
collected in both fractions but were enriched in the 100,000 g pellet
(Fig 11A, PMP70 signal of lanes 2 and 3). Using these two fractions,
we compared the recovery ratio of 3Flag-MITOL. Before valinomycin
▸Figure 10. Endogenous MITOL translocates to peroxisomes.A To generate MITOL-3Flag knock-in (KI) HCT116 cell lines, 3xFlag gene cassettes were inserted upstream of the MITOL stop codon using CRISPR/Cas9-based gene
editing. Insertion of the 3Flag-tag was verified by immunoblotting with an anti-Flag antibody. Asterisk indicates a cross-reacting band.
B The MITOL subcellular localization was observed in MITOL-3Flag KI HCT116 cells stably expressing HA-Parkin with anti-Flag, anti-catalase, and anti-Hsp60 antibodies.
Endogenous MITOL (detectable with an anti-Flag antibody) overlapped with Hsp60 under steady-state conditions, whereas 3 h of valinomycin (10 lM) treatment
induced translocation of endogenous MITOL from mitochondria to peroxisomes. Higher magnification images of the boxed regions are shown in the bottom panel.
Scale bars, 10 lm.
C Correlation statistics for the localization of endogenous MITOL-3Flag with catalase. Dots indicate individual Pearson correlation coefficient data points. In the box-
plots, the center lines show the medians, box limits indicate the 25th and 75th percentiles as determined by the R software package, and whiskers extend 1.5 times the
interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and the X-axis, respectively. Statistical significance
was calculated using a one-tailed Welch’s t-test.
D The extraction of endogenous MITOL from depolarized mitochondria is blocked by the p97/VCP inhibitor NMS-873. Higher magnification images of the boxed regions
are shown in the lower panel. Scale bars, 10 lm.
E Correlation statistics for the localization of endogenous MITOL and PMP70 in the presence of NMS-873. Dots indicate individual Pearson correlation coefficient data
points. In the box-plots, the center lines show the medians, box limits indicate the 25th and 75th percentiles as determined by the R software package, and whiskers
extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples are shown on the box and the X-axis, respectively.
Statistical significance was calculated using a one-tailed Welch’s t-test.
F Endogenous MITOL is ubiquitylated following valinomycin treatment. After MITOL-3Flag KI HCT116 cells stably expressing HA-Parkin were treated with valinomycin
for 3 h, the collected cell lysates were immunoprecipitated with anti-Flag magnetic beads. The immunoprecipitates were blotted using anti-Flag and anti-ubiquitin
antibodies. Red bars indicate ubiquitylation; the black arrowhead indicates MITOL-3Flag.
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treatment, a large proportion (ca. 80%) of the 3Flag-MITOL was
collected in the 3,000 g pellet (i.e., mitochondria-enriched fraction)
and a minor proportion (ca. 20%) in the 100,000 g pellet (i.e., perox-
isome-enriched fraction; Fig 11B). In contrast, the ratio of 3Flag-
MITOL recovered in the peroxisome-rich 100,000 g pellet increased
from 20.4% to 36.9% following valinomycin treatment for 3 h
(Fig 11B). This result supports our model that MITOL redistributes
from damaged mitochondria to peroxisomes.
To quantify the proportion of endogenous MITOL in mitochon-
dria/peroxisomes, we repeated the cellular fractionation using
MITOL-3Flag knock-in HCT116 cells stably expressing HA-Parkin.
As in the overexpressed MITOL analysis (Fig 11A and B), we
compared the ratio of endogenous MITOL recovered in the 3,000 g
and 100,000 g pellets following valinomycin treatment. Endogenous
MITOL was largely (ca. 72%) detected in the mitochondria-enriched
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Figure 11. Subcellular fractionation confirms the redistribution MITOL from depolarized mitochondria to peroxisomes.
A Distribution of exogenous 3Flag-MITOL in the mitochondria-rich or peroxisome-rich fraction following cellular fractionation. HCT116 cells stably expressing HA-
Parkin and 3Flag-MITOL were subjected to fractionation and detected using anti-Tom20, anti-PMP70, and anti-Flag antibodies. Tom20 and PMP70 were used as
mitochondrial and peroxisomal markers, respectively. The 3,000 g and 100,000 g pellets represent the mitochondria-rich and peroxisome-rich fractions.
B The recovery ratio of 3Flag-MITOL between the mitochondria-enriched (3,000 g pellet) and peroxisome-enriched fraction (100,000 g pellet) following valinomycin
treatment for the indicated times. The ratio of peroxisome-localized 3Flag-MITOL to mitochondria-localized 3Flag-MITOL increased with valinomycin treatment for
3 h. Graphic data represent results of two biological replicates. In scatter plot, dots indicate individual data points. Black dots indicate the ratio of 3Flag-MITOL
collected in the mitochondria-enriched fractions, and red dots are the ratio of 3Flag-MITOL collected in the peroxisome-enriched fractions. Mean values are also
shown.
C, D Distribution of endogenous MITOL in the mitochondria-rich or peroxisome-rich fraction following cellular fractionation. The distribution of endogenous MITOL was
examined as in (A) and (B) using MITOL-3Flag knock-in HCT116 cells. Treatment of cells with valinomycin for 3 h reduced the amount of endogenous MITOL in the
mitochondria-enriched fraction, but concomitantly increased endogenous MITOL in the peroxisome-enriched fraction. Graphic data represent results of two
biological replicates. In scatter plot, dots indicate individual data points. Black dots indicate the ratio of MITOL-3Flag collected in mitochondria-enriched fractions,
and red dots are the ratio of MITOL-3Flag collected in the peroxisome-enriched fractions. Mean values are also shown.
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peroxisome-enriched 100,000 g pellet prior to valinomycin treat-
ment (Fig 11D). Treatment of cells with valinomycin for 3 h caused
the proportion of endogenous MITOL localized on mitochondria to
decrease from 72% to 45% (Fig 11C, lane 5), but to increase from
28% to 55% in the peroxisome-enriched 100,000 g pellet (Fig 11C,
lane 6). These results confirm our immunocytochemical data indi-
cating that endogenous MITOL also redistributes to peroxisomes
following valinomycin treatment.
MITOL lacking the eight most C-terminal amino acids
(MITOLΔC8) causes peroxisome expansion following
CCCP treatment
Then what is the functional relevance of MITOL translocation to
peroxisomes? It is unlikely that MITOL is transported to peroxi-
somes because it is cytotoxic when retained on damaged mitochon-
dria. If so, it should be sufficient for MITOL to be degraded like
other Parkin substrates. We surmise that translocation of MITOL is
not to eliminate MITOL, but rather to assist MITOL function on
peroxisomes. During systematic deletion analyses of MITOL, we
happened to find that a MITOL mutant lacking the eight most C-
terminal amino acids (MITOLΔC8) caused peroxisome expansion
after CCCP treatment in the presence of Parkin (Fig 12A). To quan-
tify the effect of MITOLΔC8 on peroxisomal size and abundance,
HeLa cells expressing HA-Parkin and wild-type or ΔC8 MITOL were
treated with 15 lM CCCP for 3 h, and then the number of peroxi-
somes was counted as PMP70-positive dots per area (100 lm2). The
number of peroxisomes in cells expressing MITOLΔC8 was signifi-
cantly reduced relative to cells expressing wild-type MITOL
(Fig 12C). In addition, we compared the approximate size of peroxi-
somes (determined by the number of pixels occupied by one peroxi-
some) and found a drastic expansion of peroxisomes after CCCP
treatment in cells expressing MITOLΔC8 (Fig 12D). To examine
whether the E3 activity of MITOL is required for this expansion, we
generated two mutants, one in which Cys65/Cys68 within the RING
domain was changed to Ser (CS) and another in which the
conserved Zn-binding His43 was replaced with Trp (H43W). Both of
the E3-inactive MITOL mutants with the C-terminal eight amino acid
deletion (CS/ΔC8 and H43W/ΔC8) localized to peroxisomes follow-
ing CCCP treatment but did not trigger peroxisome expansion
(Fig 12B; higher background peroxisomal signals in the absence of
CCCP treatment are derived from CS and H43W mutants, as
described in Fig 3B). The C-terminal eight amino acid deletion
might convert MITOL to a constitutive-active form via de-repres-
sion. Following ubiquitin immunostaining, a signal that overlapped
with MITOLΔC8 was observed on enlarged peroxisomes as well as
on Parkin-ubiquitylated damaged mitochondria (Fig 13A). This
peroxisomal ubiquitylation signal was absent in cells expressing the
E3-inactive MITOL mutant (Fig 13B). These results indicate that
peroxisomes are highly ubiquitylated by translocated MITOLΔC8
following CCCP treatment, suggesting that MITOL potentially regu-
lates both the abundance and size of peroxisomes.
Discussion
PINK1 and Parkin direct mitochondria with reduced membrane
potentials toward degradation. During this process, a large number
of the outer mitochondrial membrane (OMM) proteins are ubiquity-
lated. Here, we show for the first time that MITOL migrates from
damaged mitochondria to peroxisomes depending on Parkin-
catalyzed ubiquitylation. We have elucidated in detail the molecular
mechanism underlying the translocation of MITOL to peroxisomes,
and found that (i) newly synthesized MITOL is integrated into
the OMM via Tom70, (ii) mitophagy stimulation triggers Parkin-
dependent ubiquitylation of MITOL K268 that is essential for
translocation, and (iii) p97/VCP and Pex3/16 assist in the transloca-
tion of K268-ubiquitylated MITOL from damaged mitochondria to
peroxisomes. Since Tom70 knockdown did not result in peroxisome
localization of MITOL, it seems that mitochondrial localization is a
prerequisite for MITOL translocation (Fig 5). Conversely, when
peroxisomal translocation was blocked by Pex19 depletion (Fig 6),
MITOL was retained on mitochondria. Therefore, the peroxisome is
not necessary for either mitochondrial targeting or localization of
MITOL.
Although atypical, there are examples of a limited number of
OMM proteins that escape Parkin-mediated degradation on
mitochondria, and translocate to the other organelle. FKBP38 and
Bcl-2 translocate from damaged mitochondria to the ER during
Parkin-mediated mitophagy [60]. In their study of the basis
▸Figure 12. MITOL lacking C-terminal 8 amino acids (MITOLΔC8) causes expansion of peroxisomes following CCCP treatment.A HeLa cells expressing HA-Parkin and wild-type 3Flag-MITOL or 3Flag-MITOL lacking C-terminal 8 amino acids (ΔC8) were treated with 15 lM CCCP for 3 h, and then
subjected to immunocytochemistry with anti-Flag and anti-PMP70 antibodies. Expanded peroxisomes were observed in MITOLΔC8-expressing cells. Higher
magnification images of the boxed regions are shown in the small panel. Scale bars, 10 lm.
B 3Flag-MITOLΔC8 with the E3-inactive Cys65Ser/Cys68Ser (CS) and H43W mutations were transfected into HeLa cells stably expressing HA-Parkin, treated with 15 lM
CCCP, and then subjected to immunocytochemistry with anti-Flag and anti-PMP70 antibodies. After 3 h of CCCP treatment, both the CS and H43W mutants localized
on peroxisomes but expansion was not observed. Scale bars, 10 lm.
C HeLa cells expressing HA-Parkin and MITOL wild-type or ΔC8 were treated with 15 lM CCCP for 3 h, and the number of peroxisomes was counted as PMP70-positive
dots per 100 lm2. In the box-plots, dots indicate individual data points, the center lines show the medians, box limits indicate the 25th and 75th percentiles as
determined by the R software package, and whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Means and the number of samples
are shown on the box and the X-axis, respectively. Statistical significance was calculated using a one-tailed Welch’s t-test. The abundance of peroxisomes in cells
expressing MITOLΔC8 was significantly decreased as compared with cells expressing wild-type MITOL.
D MITOLΔC8 causes a drastic expansion of peroxisomes following CCCP treatment. HeLa cells expressing HA-Parkin and wild-type or ΔC8 MITOL were treated with
15 lM CCCP for 3 h, and the approximate size of peroxisomes was determined as the number of pixels occupied by one peroxisome. The PMP70-positive pixels per
100 lm2 were divided by the number of peroxisomes in the same area. In the box-plots, dots indicate individual data points, the center lines show the medians, box
limits indicate the 25th and 75th percentiles as determined by the R software package, and whiskers extend 1.5 times the interquartile range from the 25th and 75th
percentiles. Means and the number of samples are shown on the box and the X-axis, respectively. Statistical significance was calculated using a one-tailed Welch’s
t-test.
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underlying the mitochondria retention of Bcl-XL and Omp25 (neither
targets to the ER despite topologies comparable with FKBP38 and
Bcl-2) during mitophagy, Saita et al found that the number of basic
amino acids in the C-terminus determined the protein fates. Muta-
tional analyses of the FKBP38, Bcl-2, and Bcl-XL revealed that one
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translocation to the ER, whereas two or more basic amino acids in the
C-terminal region resulted in mitochondrial retention and subsequent
degradation in response to mitophagy.
In this report, we showed that the MITOL C-terminal residue
K268 is essential for escape from damaged mitochondria (Fig 9).
Since K268 is a basic amino acid in the MITOL C-terminus, the
molecular mechanism underlying MITOL translocation could be
similar to that of FKBP38 and Bcl-2 [60]. However, multiple points
suggest that the mechanisms are completely different. First, FKBP38
and Bcl-2 are tail-anchored proteins, and it is unknown whether the
C-terminal region, which determines translocation from mitochon-
dria to the ER, faces the cytoplasmic or luminal side. The MITOL
C-terminus, in contrast, is oriented toward the cytoplasmic side as
evidenced by Parkin-mediated ubiquitylation of K268 (Fig 9).
Second, although the E3 activity of Parkin is required for FKBP38 to
translocate from depolarized mitochondria to the ER, it is unknown
whether the C-terminal regions of FKBP38 undergo ubiquitylation
similar to MITOL. Third, in the case of FKBP38 and Bcl-2, both K
and R residues in the C-terminus can direct the proteins from the
mitochondria to the ER, whereas in the case of MITOL, the K268R
mutation hampered translocation from mitochondria to peroxisomes
(Fig 9). For MITOL, the more important factor is whether the
C-terminal K undergoes ubiquitylation rather than the presence of
the basic residue itself.
Regarding mitochondria-to-peroxisome transport, mitochondria-
derived vesicles (MDVs) have been reported. The OMM RING finger
protein MAPL/MuL1/MULAN was incorporated into MDVs via a
Vps35-dependent mechanism and transported to peroxisomes, but
this process was independent of PINK1 and Parkin [61,62]. More-
over, only 10–20% of the total peroxisomes were MAPL positive,
suggesting MAPL translocates to specific subpopulations of peroxi-
somes [63]. In contrast, MITOL-positive small dots predominantly
coincided with all peroxisomes following mitophagy stimulation.
MAPL-positive MDVs were generated from the curvature of the
OMM; however, it is unknown whether the transit of MAPL-positive
MDVs to peroxisomes requires VCP. Given that VCP is involved in
protein extraction rather than vesicular formation in general, our
results (Fig 8) suggest that not vesicular formation but selective
MITOL extraction from the OMM is involved. The molecular mecha-
nisms underlying MITOL redistribution from damaged mitochondria
to peroxisomes might be completely different than those of MAPL.
Ubiquitin determines subcellular localization of various substrate
proteins. For example, ubiquitylation accelerates a number of
protein transport events including the following: from the plasma
membrane to early endosomes in endocytosis, from the surface of
late endosomes to the multivesicular body, from cytosol/plasma
membrane to the virus particles during virus budding, from the ER
to cytosol in ER-associated degradation, and from various organelles
to autophagosomes in selective autophagy. Here we found that
ubiquitylation functions as a new signal for mitochondria-to-peroxi-
some transport. By what mechanism does MITOL translocate to
peroxisomes in response to ubiquitylation? Various other ubiquity-
lated OMM proteins such as MitoNEET/CISD1, Fis1, Miro1/2,
Tom20, and Tom70 do not translocate to peroxisomes during
Parkin-mediated mitophagy (Fig 4), indicating that the peroxisomal
targeting of MITOL is not solely attributable to ubiquitylation. We
think the most reasonable hypothesis is that MITOL has both peroxi-
somal localization and mitochondrial localization sequences, but
that the latter targeting signal is dominant. Dysfunction of the mito-
chondrial localization sequence by C-terminal ubiquitylation in
response to Parkin-mediated mitophagy triggers the usually latent
peroxisomal localization sequence and promotes MITOL transloca-
tion to the peroxisome. We have found that VCP is essential for
MITOL localization to peroxisomes—this VCP involvement is a
unique aspect of MITOL translocation that has not been reported for
either FKBP38 or Bcl-2. Ubiquitylation plays an essential role in
VCP-based recognition [64]. Taken together, when Parkin ubiquity-
lates MITOL K268, the ubiquitin assists in MITOL mitochondrial
release via VCP-based recognition, and at the same time this ubiqui-
tin suppresses the mitochondrial localization signal, which allows
the peroxisome localization signal to manifest.
On the other hand, this translocation event raises new questions
regarding its purpose. OMM proteins ubiquitylated by Parkin are
recognized by the proteasome for prompt degradation, or they are
recognized by autophagy adaptor/receptor proteins such as OPTN
and NDP52 for degradation via the lysosome [6–9,65]. Thus, OMM
proteins ubiquitylated by Parkin are essentially destined for degrada-
tion. If MITOL is unnecessary or cytotoxic on damaged mitochon-
dria, it should be sufficient for MITOL to be targeted for degradation
like other OMM proteins. However, MITOL was not degraded follow-
ing Parkin-catalyzed ubiquitylation; instead translocated to peroxi-
somes. These results suggest that translocation of MITOL is not to
eliminate MITOL, but rather to assist in retention of MITOL on
peroxisomes. Although the functional relevance of ubiquitin-depen-
dent MITOL translocation to peroxisomes has not been unveiled
completely, we obtained an important clue to the significance. As
shown in Fig 12, in the presence of Parkin, the MITOL mutant lack-
ing the eight most C-terminal amino acids (MITOLΔC8) induced both
peroxisome expansion and a reduction in peroxisomal abundance
following CCCP treatment. Ubiquitin was accumulated on expanded
peroxisomes in MITOLΔC8-expressing cells, whereas E3-inactive
MITOLΔC8 mutants failed to lead ubiquitylation and expansion of
peroxisomes (Figs 12 and 13). Mitochondria and peroxisomes share
some metabolic pathways, and to maintain cellular homeostasis their
distribution and abundance are highly coordinated [45,66–68]. As
such, it is possible that MITOL plays a critical role in balancing the
two organelles when mitochondria are damaged. More detailed explo-
rations of this potential homeostatic mechanism warrant future study.
◀ Figure 13. MITOLΔC8 ubiquitylates expanded peroxisomes following CCCP treatment.A, B HeLa cells expressing HA-Parkin and MITOLΔC8 (A) or MITOLΔC8 lacking E3 activity (B) were treated with 15 lM CCCP for 3 h, and then subjected to
immunocytochemistry with anti-Flag and anti-ubiquitin antibodies. Expanded peroxisomes were ubiquitylated upon E3 activity of MITOL. Higher magnification
images of the boxed regions are shown in the small panel. Scale bars, 10 lm.
C The schematic model of PINK1/Parkin-mediated MITOL redistribution. MITOL is targeted to mitochondria with sustained membrane potential via Tom70. In
response to mitophagy stimuli, Parkin-catalyzed ubiquitylation of MITOL causes its extraction from damaged mitochondria in a p97/VCP-dependent manner, and
then, MITOL translocates to peroxisomes via Pex3/Pex16 pathway. As ubiquitylation of MITOL is rarely observed in the absence of NMS-873, MITOL inserted into the
peroxisome membrane is shown here in the non-ubiquitylated form.
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In total, this study demonstrates a novel function for Parkin-cata-
lyzed ubiquitylation in the translocation of a mitochondrial protein
to peroxisomes (Fig 13C) and provides new significance regarding
ubiquitylation of damaged mitochondrial proteins.
Materials and Methods
Plasmids and antibodies
To construct plasmids for transient expression of MITOL-GFP,
MITOL-HA, MITOL-3Flag, and 3Flag-MITOL, the MITOL coding
sequence was amplified from a HeLa cDNA library and inserted into
the HindIII/KpnI sites of pEGFP-N1 (Clontech), pcDNA (Invitrogen),
and pcDNA3.1 (Invitrogen) to generate C-terminal GFP, HA, and
3Flag tags, respectively. For stable expression of MITOL, the MITOL
coding sequence was inserted into the BamHI/EcoRI sites of the
pMXs-Puro retroviral expression vector (CELL BIOLABS, INC.)
harboring the 3Flag-tag sequence. The MITOL C65S/C68S (CS),
H43W, K268A/R, K54A/R, or K40A/R mutations were introduced by
primer-based PCR mutagenesis. The PBR-HA plasmid was kindly
gifted by Dr. Endo (Kyoto Sangyo University). To prepare the PBR-
3Flag plasmid, the DNA fragment encoding PBR was inserted into
BamHI/EcoRI sites of the pcDNA3.1 vector containing the 3Flag
sequence. For transient expression of PMP34-FusionRed, the
FusionRed coding sequence (Evrogen) was inserted into the pcDNA
vector to generate the pcDNA-FusionRed plasmid. Then, the PMP34
coding sequence was inserted into the HindIII/KpnI sites of the
pcDNA-FusionRed plasmid. pcDNAZeo/RnPEX3-HA2, pcDNAZeo/
HA3-HsPEX16, and pcDNAZeo/HA2-HsPEX19 were generated as
described previously [69,70,71]. The pCMV2/Flag-p97/VCP was
described previously [72] and E305Q/E578Q (p97QQ) plasmid was
gifted by Dr. Kakizuka (Kyoto University). The GFP-Parkin, Flag-
Parkin, and Su9-GFP plasmids were generated as described previously
[4,73]. For doxycycline-inducible expression, the 3FLAG-MITOL coding
sequence was inserted into the SalI/BamHI sites of the pTRE3G-IRES
vector (MBL) to generate pTRE3G-3Flag-MITOL plasmid.
The following antibodies were used for immunoblotting: anti-
Flag (Cat. # PM020, MBL or FLA-1, Cat. # M185-3L, MBL, 1:1,000),
anti-Tom70 (a kind gift from Dr. Otera, Kyushu University, 1:1,000),
anti-Tom20 (FL145, Cat. # sc-136211, RRID:AB_2207538, Santa
Cruz, 1:500–1:1,000), anti-Tom40 (a kind gift from Dr. Oka, Rikkyo
University, 1:1,500), anti-Sam50 (EPR8718, Cat. # ab133709,
Abcam, 1:500), anti-AIF (E-1, Cat. # sc-13116, RRID:AB_626654,
Santa Cruz, 1:1,000), anti-GFP (Cat. # ab6556, RRID:AB_305564,
Abcam, 1:2,000), anti-p97/VCP (Cat. # ab11433, RRID:AB_298039,
Abcam, 1:1,000), anti-Tubulin (Cat. # ab6160, RRID:AB_305328,
Abcam, 1:1,000), anti-LDH (Cat. # ab2101, RRID:AB_302839,
Abcam, 1:1,000), anti-PMP70 (Cat. # SAB4200181, RRID:
AB_10639362, SIGMA, 1:1,000), and anti-Ubiquitin (P4D1, Cat. # sc-
8017, RRID:AB_628423, Santa Cruz, 1:1,000), anti-mitofusin2 (Cat.
# ab56889, RRID:AB_2142629, Abcam, 1:500), anti-MTCO2 anti-
body (12C4F12, Cat. # ab110258, Abcam, 1:500).
The following antibodies were used for immunocytochemistry:
anti-HA (TANA2, MBL, 1:1,000), anti-Flag (Cat. # PM020, MBL or
FLA-1, Cat. # M185-3L, MBL, 1:1,000), anti-Catalase (1A1, Cat.
# LF-MA0003, RRID:AB_1611839, AbFrontier, 1:200), anti-Pex14 (Cat.
# ABC142, Millipore, 1:200), anti-PMP70 (Cat. # SAB4200181, RRID:
AB_10639362, SIGMA, 1:200), anti-Sec61b (Cat. # 07-205, RRID:
AB_11212145, Upstate, 1:3,000), anti-LAMP1 (H4A3, Cat. # sc-20011,
RRID:AB_626853, Santa Cruz, 1:300), anti-Tom20 (FL-145, Cat. # sc-
136211, RRID:AB_2207538, Santa Cruz, 1:1,000), anti-Hsp60 (Cat. #
N-20, Santa Cruz, 1:250), anti-MitoNEET/CISD1 (Cat. # 16006-1-AP,
RRID:AB_2080268, ProteinTech, 1:250), anti-Fis1 (a kind gift from Dr.
Oka, Rikkyo University, 1:250), anti-Miro1 (Cat. # HPA016087, RRID:
AB_1079813, SIGMA, 1:200), anti-Miro2 (Cat. # 11237-1-AP, RRID:
AB_2179539, ProteinTech, 1:200), anti-Drp1 (8/DLP1, Cat. # 611113,
BD Transduction Laboratories, 1:200), anti-mitofusin1 (3C9, Cat. #
H00055669-M04, RRID:AB_581724, Abnova, 1:200), anti-Tom70 (a
kind gift from Dr. Otera, Kyushu University, 1:200), and anti-Ubiquitin
(P4D1, Cat. # sc-8017, RRID:AB_628423, Santa Cruz, 1:100).
Cell culture and transfections
HeLa cells and SH-SY5Y cells were cultured at 37°C with 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) containing 1×
nonessential amino acids (Gibco), 1× sodium pyruvate (Gibco), 1×
penicillin–streptomycin–glutamine (Gibco), and 10% fetal bovine
serum. HCT116 cells were cultured in McCoy’s 5A medium (Gibco)
supplemented with 1× nonessential amino acids (Gibco), 10% fetal
bovine serum, and 1× GlutaMAX (Gibco). PINK1 knockout HeLa cells
and USP30 knockout HeLa cells were prepared as previously reported
[41,55]. To generate HeLa cells stably expressing HA-Parkin or GFP-
Parkin, HeLa cells transiently expressing mCAT1 (murine cationic
amino acid transporter-1) were infected with recombinant retroviruses
harboring HA-Parkin or GFP-Parkin. Recombinant retroviruses were
produced using PLAT-E cells as described previously [12].
HeLa cells and HCT116 cells stably expressing 3Flag-MITOL and
HA-Parkin were established by recombinant retrovirus infection.
Vector particles were produced in HEK293T cells by co-transfection
with Gag-Pol, VSV-G, and the retrovirus plasmids using Lipofec-
tamine LTX Reagent (Thermo Fisher Scientific) [40]. After 12 h of
transfection, the culture medium was replaced with fresh medium.
The cells were further cultivated for 24 h. Collected viral super-
natants were then used to infect HeLa cells or HCT116 cells using
8 lg/ml polybrene (SIGMA). Plasmid transfections were performed
using FuGENE6 (Promega) or polyethylenimine (Polyscience Inc.)
according to the manufacturer’s instructions.
To depolarize mitochondria, cells were treated with 15 lM
carbonyl cyanide m-chlorophenylhydrazone (CCCP; Wako) or
10 lM valinomycin (SIGMA) for 3 h unless otherwise specified. To
inhibit proteasome activity, 10 lM MG132 (SIGMA) was used, and
to inhibit p97/VCP activity, 10 lM NMS-873 (SIGMA) was used. To
prevent SH-SY5Y cell death in response to the valinomycin treat-
ment, an apoptosis inhibitor, Z-VAD-FMK (Peptide Institute), was
included in the incubation.
Dox-inducible expression system
The pTRE3G-3Flag-MITOL and pCMV-Tet3G plasmids were co-
transfected into HeLa cells stably expressing HA-Parkin. After 24 h,
doxycycline (100 ng/ml; Clontech) was added to cells for 3 h. The
cells were then repeatedly washed with fresh media, and treated
with 15 lM CCCP for 3 h to induce mitochondrial depolarization.
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Subcellular fractionation
HCT116 cells stably expressing HA-Parkin and 3Flag-MITOL, or
MITOL-3Flag knock-in HCT116 cells stably expressing HA-Parkin,
were harvested in homogenization buffer [20 mM HEPES–NaOH,
pH 7.5, 0.25 M sucrose, 1 mM DTT, 2 mM EGTA, and protease
inhibitor cocktail EDTA-free (Roche)]. Cells were homogenized
using four strokes of a Potter-Elvehjem homogenizer and then
centrifuged at 800 g for 5 min to obtain a post-nuclear super-
natant (PNS). The PNS fraction was further separated into super-
natant and pellet fractions by centrifugation at 3,000 g for
10 min. The 3,000 g supernatant fraction was then centrifuged at
100,000 g for 30 min to yield a 100,000 g pellet fraction. Each
fraction was suspended in the same volume as the PNS fraction,
and identical sample volumes were loaded on gels for
immunoblotting. For separation of cytosolic and mitochondria-
enriched fractions in siTom70-treated cells, the cells were
harvested in a modified homogenization buffer [10 mM HEPES–
NaOH, pH 7.5, 0.25 M sucrose, protease inhibitor cocktail, EDTA-
free (Roche), and 10 lM NMS-873] and homogenized by passing
through a 27-gauge needle seven times. After centrifugation at
1,000 g for 10 min, a PNS was collected. The PNS was further
centrifuged at 20,400 g for 10 min to obtain cytosolic and mito-
chondria-enriched fractions. Each band was quantified using
ImageQuant TL (GE Healthcare).
RNA interference
Non-targeting control siRNA and siRNA oligos for p97/VCP were
described previously. The siRNA oligonucleotide sequences are as
follows: control, 50-CGUUAAUCGCGUAUAAUACGCGUAT-30; p97/
VCP, 50-CGGGAGAGGCGCGCGCCAUTT-30 [74,75]. For siRNA
knockdown of Pex3, Pex16, and Pex19, Stealth siRNA (HSS112408,
HSS145149, and HSS108913, respectively) were purchased from
Invitrogen. The siRNA oligonucleotide sequences are as follows:
Pex3, 50-GGGAGGAUCUGAAGAUAAUAAGUUU-30; Pex16, 50-GGAU
CCUACGGAAGGAGCUUCGGAA-30; Pex19, 50-AGAAUGGUUGCAGA
GUCAUCGGGAA-30. siRNAs were transfected into cells using Lipo-
fectamine RNAiMAX (Invitrogen) according to the manufacturer’s
instruction. After 24 h of transfection, the medium was replaced
with fresh medium and the cells were grown for another 24 h. For
co-transfection of siRNA and plasmid DNA, Lipofectamine 2000
(Invitrogen) was used according to the manufacturer’s instruction.
After 6 h of transfection, the medium was replaced with fresh
medium and the cells were grown for another 42 h. For knockdown
of Tom40 and Sam50, siGENOME Human siRNA SMARTpools were
purchased from Thermo Scientific. The target sequences are as




U-30, 50-GAACAAGCAACUCAUAUUU-30. For knockdown of Tom20,
and Tom70, FlexiTube siRNAs (SI00301959 and SI00301973, respec-
tively) were purchased from QIAGEN. The target sequences were as
follows: Tom20/TOMM20, 50-AAAGTTACCTGACCTTAAAGA-30;
Tom70/TOMM70A, 50-AGACAAATAAGAAGGAATGTT-30. siRNAs
were transfected to HeLa cells twice within a 24-h interval. After
72 h of initial transfection, cells were transfected with Su9-GFP and
3Flag-MITOL plasmids using FuGENE6 (Promega). After 16 h of
plasmid transfection, cells were fixed with 4% paraformaldehyde
and subjected to immunostaining and subcellular fractionation.
CRISPR/Cas9-based generation of a PEX19 knockout cell line
PEX19/ HCT116 cells were established by CRISPR/Cas9-based
genome editing with an antibiotic-selection strategy. The gRNA
target sequence for the region of exon 1 in the PEX19 gene (50-GT
GTCGGGGCCGAAGCGGACAGG-30) was selected using an online
CRISPR design tool (CRISPRdirect). Two DNA oligonucleotides,
hPex19-ex1-1-CRISPR-F (50-TGTATGAGACCAC GTGTCGGGGCCGA
AGCGGAC-30) and hPex19-ex1-1-CRISPR-R (50-AAAC GTC CGC TTC
GGC CCC GAC AC GTGGTCTCA-30) were annealed and introduced
into a linearized pEF1-hspCas9-H1-gRNA vector (Cas9 SmartNucle-
aseTM; System Biosciences, LLC) according to the manufacturer’s
protocol. The DNA fragment was verified by DNA sequencing.
Neomycin- and hygromycin-resistant marker plasmids were
constructed as follows. The neomycin-resistant gene (NeoR), includ-
ing loxP sites along with the appropriate promoter and terminator,
was PCR-amplified from pMK286 [59] using BamHI-NeoR-F (50-ggc
cGG ATC Cct aat taa cta gAT AAC TTC GTA TAA TGT ATG CTA
TAC GAA GTT ATc tga ggc gga aag aa-30) and NeoR-BamHI-R (50-
GGC Cgg atc cAT AAC TTC GTA TAG CAT ACA TTA TAC GAA GTT
Ata acg acc caa cac cg-30) primers. The hygromycin-resistant gene
(HygroR), including loxP sites with appropriate promoter and termi-
nator, was PCR-amplified from pMK287 [59] using BamHI-HygroR-F
(50-ggc cGG ATC Cct aat taa cta gAT AAC TTC GTA TAA T-30) and
HygroR-BamHI-R (50-ggc cGG ATC Cta gtg aac ctc ttc g-30) primers.
The amplified NeoR and HygroR fragments were digested with
BamHI and ligated into the corresponding site of pBluescript II SK(-)
to make pBSK/NeoR and pBSK/HygroR, respectively. The 247 bp of
the 50 and 30 homology arms of the PEX19 exon 1 region, which
lacks the gRNA target sequence but has a BamHI site in the middle
(total 500 bp), was synthesized and cloned into a pUC57-Amp
vector (GENEWIZ) to make pUC57-Amp/PEX19-ex1-donor. NeoR
and HygroR resistant markers extracted by BamHI digestion from
pBSK/NeoR and pBSK/HygroR were then inserted into the BamHI
site of pUC-Amp/PEX19-ex1-donor. The resultant NeoR and HygroR
donor plasmids containing the PEX19 exon 1 homology arm were
transfected into HCT116 cells with the gRNA plasmid using
FuGENE6 (Promega). Cells were grown in McCoy’s 5A media
containing 700 lg/ml G418 (G8168; SIGMA) and 100 lg/ml hygro-
mycin B (10687-10, Invitrogen). PEX19/ single clones were
screened by PCR using genomic DNA to verify neomycin-resistant
and hygromycin-resistant gene insertion. To verify insertion of the
resistant markers, the following primers were used; hPex19-ex1-1-
check-F2 (50-CGCCAGGTAATTTGGGAAGTTG-30), hPex19-ex1-1-
check-R2 (50-CCTGCCCGTCCCTAATATCTC-30). The absence of
peroxisomes in PEX19/ cells was further confirmed by
immunostaining with anti-Catalase and anti-Pex14 antibodies.
Generation of a MITOL-3Flag knock-in cell line
MITOL-3Flag knock-in HCT116 cells were established using
CRISPR/Cas9-based genome editing with an antibiotic-selection
strategy. The gRNA target sequence for the region of exon 6 in the
MITOL gene (50-AGAAATATAATAAAGCACTTAGG-30) was selected
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using an online CRISPR design tool (CRISPRdirect). Two DNA
oligonucleotides, hMITOL-ex6-3-CRISPR-KI-F (50-TGTATGAGACCA
C AGAAATATAATAAAGCACTT-30) and hMITOL-ex6-3-CRISPR-KI-
R (50-AAAC AAG TGC TTT ATT ATA TTT CT GTGGTCTCA-30)
were annealed and introduced into a linearized pEF1-hspCas9-H1-
gRNA vector (Cas9 SmartNucleaseTM; System Biosciences, LLC)
according to the manufacturer’s protocol. The DNA fragment was
verified by DNA sequencing. Neomycin- and hygromycin-resistant
marker plasmids were constructed as follows. The neomycin-resis-
tant gene (NeoR), including 3Flag was amplified by PCR from
pMK283 [59] using pMK283,284_BamHI(F) (50-AAA gga tcc ggt
gca ggc gcc AAG GAA-30) and pMK277,283_BamHI(R) (50-CCC
GGA TCC AAC GAC CCA ACA CCG TGC-30) primers. The hygro-
mycin-resistant gene (HygroR), including 3Flag was amplified by
PCR from pMK284 [59] using pMK283,284_BamHI(F) (50-AAA gga
tcc ggt gca ggc gcc AAG GAA-30) and pMK278,284_BamHI(R) (50-
CCC GGA TCC TAG TGA ACC TCT TCG AGG-30) primers. The
247 bp of the 50 and 30 homology arms of the MITOL exon 6
region, which lacks the gRNA target sequence but has a BamHI
site in the middle (total 500 bp), was synthesized and cloned into
a pUC57-Amp vector (GENEWIZ) to make pUC57-Amp/MITOL-ex6-
donor. The PCR-amplified 3Flag-NeoR and 3Flag-HygroR resistant
markers were extracted by BamHI digestion and then inserted into
the BamHI site of pUC-Amp/MITOL-KI-ex6-donor. The resultant
3Flag-NeoR and 3Flag-HygroR donor plasmids containing the MITOL
exon 6 homology arm were transfected into HCT116 cells with the
gRNA plasmid using FuGENE6 (Promega). Cells were grown in
McCoy’s 5A media containing 700 lg/ml G418 (G8168, SIGMA) and
100 lg/ml hygromycin B (10687-10, Invitrogen). After 48 h, cells
were expanded with neomycin and hygromycin-containing McCoy’s
media. MITOL-3Flag knock-in HCT116 cell single clones were
screened by immunoblotting using an anti-Flag antibody.
Immunoblotting
HeLa cells were solubilized with TNE-N+ buffer [20 mM Tris–HCl,
pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and protease inhi-
bitor cocktail complete EDTA-free (Roche) in the presence of 1 mM
N-ethylmaleimide (NEM)]. After removing insoluble debris by
centrifugation, the supernatant was collected to obtain total cell
lysates. The total protein concentration of the lysates was deter-
mined using a BCA Protein Assay Kit or a 660 nm Protein Assay
Reagent (Pierce). SDS–PAGE sample buffer was added to lysates,
and samples were boiled at 98°C for 5 min. Proteins were separated
on 4–12% Bis-Tris SDS–PAGE gels (NuPAGE; Invitrogen) in MOPS
buffer. Proteins were transferred to PVDF membranes (Merck),
blocked with 5% skim milk/TBST, and incubated with primary
antibodies. Membranes were then incubated with horseradish
peroxidase-conjugated goat anti-mouse, goat anti-rabbit, and
donkey anti-rat antibodies (Cat. # 315-035-048, #111-035-144, and
#712-035-153, Jackson ImmunoResearch Inc.) as secondary anti-
bodies. Images were obtained using an ImageQuant LAS 4000 (GE
Healthcare).
Immunoprecipitation
HeLa cells grown in a 10-cm dish were solubilized with TNE-N+
buffer. After centrifugation, the supernatant was incubated with
anti-DDDDK-tag mAb Magnetic beads (M185-11; MBL) for 3 h at
4°C. The agarose was washed three times with TNE-N+ buffer, and
proteins were extracted by adding SDS–PAGE sample buffer.
Immunocytochemistry
HeLa cells were fixed with 4% paraformaldehyde (Wako), perme-
abilized with 0.15% or 0.5% Triton X-100, and incubated with
primary antibodies followed by 1:2,000 secondary antibodies [Alexa
Fluor 488-, 568-, or 647-conjugated goat or donkey anti-mouse, anti-
rabbit, or anti-goat IgG antibody (Invitrogen)]. Microscopy images
were acquired at room temperature on a laser-scanning microscope
with Plan Apochromat 63×/1.4 Oil (LSM710 or LSM780; Carl Zeiss).
Image sizes were adjusted with Photoshop software (Adobe). For
quantitative co-localization and statistical analysis, the co-localiza-
tion of MITOL with other proteins was calculated using Zen soft-
ware (Carl Zeiss) as a Pearson correlation coefficient. The number
of peroxisomes was counted as PMP70-positive dots per area
(100 lm2) in randomly selected cells. After the images were
converted into threshold images, Zen software (Carl Zeiss) was used
to calculate the PMP70-positive pixels per 100 lm2, which was then
divided by the number of peroxisomes in the same area to yield an
approximate size for peroxisomes. In the associated box-plots of the
data, the dots indicate individual Pearson correlation coefficient
data points, the center lines indicate the medians, the box limits
indicate the 25th and 75th percentiles as determined by the R soft-
ware package, and whiskers extend 1.5 times the interquartile range
from the 25th and 75th percentiles. Outliers are represented by dots
outside of the whiskers, mean values are shown on the boxes, and
the number of samples is indicated above the X-axis. Statistical
significance was calculated using a one-tailed Welch’s t-test.
LC-MS/MS-based identification of MITOL ubiquitylation sites
After valinomycin treatment for 3 h, PEX19/ HCT116 cells stably
expressing 3Flag-MITOL and HA-Parkin grown in a 10-cm dish were
treated with 0.1% paraformaldehyde at room temperature for
10 min. Then, cells were treated with 300 mM glycine at room
temperature for 3 min. After cells were washed with PBS three
times, the collected cell suspensions were centrifuged at 2,000 g for
5 min. RIPA buffer [50 mM Tris–HCl, 150 mM NaCl, 0.1% (w/v)
SDS, 0.5% (w/v) sodium deoxycholate, and 1% (v/v) Triton X-100]
supplemented with protease inhibitor cocktail complete EDTA-free
(Roche) was added to the pellet. After pipetting, cells were lysed on
ice for 10 min. After centrifugation at 14,000 g for 10 min, the
collected supernatants were incubated with anti-DDDDK-tag mAb
Magnetic beads (Cat. # M185-11, MBL) for 1.5 h at 4°C with rota-
tion. The beads were washed three times with RIPA buffer and twice
with 50 mM ammonium bicarbonate. Proteins on the beads were
digested by adding 200 ng trypsin (MS grade, Pierce) for 16 h at
37°C. The digests were reduced, alkylated, acidified and desalted
using GL-Tip SDB (GL Sciences). The eluates were evaporated in a
SpeedVac concentrator and dissolved in 0.1% trifluoroacetic acid.
LC-MS/MS analysis of the resultant peptides was performed on
an EASY-nLC 1200 UHPLC connected to a Q Exactive Plus mass
spectrometer equipped with a nanoelectrospray ion source (Thermo
Fisher Scientific). The peptides were separated on a 75 lm inner
diameter × 150 mm C18 reversed-phase column (Nikkyo Technos)
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with a linear 4–28% acetonitrile (ACN) gradient for 0–100 min
followed by an increase to 80% ACN for 10 min. The mass spec-
trometer was operated in a data-dependent acquisition mode with a
top 10 MS/MS method. MS1 spectra were measured with a resolu-
tion of 70,000, an automatic gain control (AGC) target of 1 × 106
and a mass range from 350 to 1,500 m/z. HCD MS/MS spectra
were acquired at a resolution of 17,500, an AGC target of 5×104, an
isolation window of 2.0 m/z, a maximum injection time of 60 ms
and a normalized collision energy of 27. Dynamic exclusion was
set to 10 s. Raw data were directly analyzed against the SwissProt
database restricted to H. sapiens using Proteome Discoverer version
2.2 (Thermo Fisher Scientific) with Mascot search engine version
2.5 (Matrix Science) for identification and label-free precursor ion
quantification. The search parameters were as follows: (i) trypsin
as an enzyme with up to two missed cleavages; (ii) precursor
mass tolerance of 10 ppm; (iii) fragment mass tolerance of
0.02 Da; (iv) carbamidomethylation of cysteine as a fixed modifi-
cation; and (v) acetylation of the protein N-terminus, oxidation of
methionine and di-glycine modification of lysine as variable modifi-
cations. Peptides were filtered at a false-discovery rate of 1% using
the percolator node. Normalization was performed such that the
total sum of abundance values for each sample over all peptides
was the same.
FACS-based mitophagy assay
HCT116 cells stably expressing YFP-Parkin, mt-mKeima, and 3Flag-
MITOL were grown in a 6-well plate and treated with 10 lM oligo-
mycin (Cat. # 495455; Calbiochem) and 4 lM antimycin A (Cat. #
A8674; SIGMA) for 0, 3, or 6 h. Cells were then resuspended in sort-
ing buffer (phosphate buffer with 2.5% FBS). Analysis was
performed using FACSDiva software on a BD LSRFortessa X-20 cell
sorter. mKeima was measured using dual-excitation ratiometric pH
measurements at 405 (pH 7) and 561 (pH 4) nm lasers with 610/
20 nm emission filters. For each sample, 10,000 cells of YFP/mt-
Keima double positive cells were collected.
Expanded View for this article is available online.
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